U.S. stock futures wobbled, as rising energy prices exacerbated concerns about inflation, and lingering worries about China’s property sector weighed on sentiment. Individual stocks also saw muted trading ahead Tuesday’s opening bell. Here’s what is moving:
-
shares added 2.5% after the stock was raised to outperform from market perform by Cowen.
-
shares rose 2.2%. Credit Suisse on Tuesday raised the stock’s price target to $68 per share from $33 a share. On Monday the stock closed at $44.42.
- Shares of
plunged 14% premarket after the German drug maker said its shot—once considered a promising Covid-19 vaccine candidate—would arrive too late to have a viable market. The company is shelving its most advanced Covid-19 vaccine and focusing on a new version.
-
shares fell 7% premarket Tuesday. Shares closed more than 17% higher on Monday after the healthcare device company said results were positive from a study of its tennis elbow treatment.
- Shares of cannabis company
edged up 1.4% premarket after its wholly-owned subsidiary Canna Cabana received approval to operate in British Columbia.
- Shares of
edged 1.3% higher premarket a day after it and partner Ridgeback Biotherapeutics said they have filed an application asking U.S. health regulators to authorize their Covid-19 pill, the next step toward adding a long-sought drug for use at home.
The Merck & Co. campus in Rahway, N.J., July 12, 2018.
Photo:
brendan mcdermid/Reuters
- Digital payments company
was up 1.2% ahead of the bell, with no clear news though the stock was among the trending tickers on Stocktwits.
-
shares slipped 0.8% premarket. The maker of fasteners and other industrial equipment posted a rise in sales and earnings for the third quarter, but noted that supply-chain and other input costs have risen.
Read More: Airbnb, Merck, High Tide, Square: What to Watch When the Stock Market